Resmed Inc (RMD)
割安ファンダメンタル
75
株価
$220.14
時価総額
$32.04B
パート1 · 企業の価値
概要
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$5.65B
直近12か月(2026/6/30まで)
純利益
$1.52B
直近12か月(2026/6/30まで)
フリーキャッシュフロー
$1.65B
自己資本合計
$6.59B
負債合計
$2.38B
流動比率
3.10
利払い倍率
-
負債/EBITDA
0.40
一株当たり利益(EPS)
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$347.54
現在株価
$220.14
安全マージン
+36.7%
適正価値レンジ
$225.90 - $469.18
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
21.20
ROE
23.1%
P/B レシオ
4.84
P/FCF
19.34
粗利益率
61.1%
ROIC
19.7%
収益性レーダー
価値創造(経済的モート)
ROIC
19.7%
WACC
8.5%
ROIC − WACC
+11.2 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格(19)
- EPS shows upward trend
- EPS CAGR 15.14%
- Price CAGR 13.41%
- ROIC 19.7%
- Gross Margin 61.1%
- P/FCF 19.34
- Debt/Equity ratio
- Operating Margin 33.4%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 23.9%
- Revenue Growth 5Y 12.1%
- PEG Ratio 0.79
- Earnings Quality (OCF/NI) 1.19
- Share Dilution -0.8%
- Piotroski F-Score 7/9
不合格(7)
- P/B Ratio 4.84
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 48% Buy
- Earnings Surprise avg 0.8%
- Net Margin Trend 26.9% vs 27.2%
データなし(2)
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-スコア
財務健全性が高い
利益の質
高品質:利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Chairman | 53 |
| Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD | Founder, Chair Emeritus & Non-Executive Director | 83 |
| Mr. Michael J. Rider | Chief Legal Officer & Secretary | 67 |
| Mr. Brett A. Sandercock | Advisor | 58 |
| Mr. Justin Leong | Chief Product Officer | 47 |
| Mr. Aaron Bloomer | Chief Financial Officer | 39 |
| Mr. Alastair Robertson | Chief Information Officer | - |
| Ms. Sallilyn Schwartz | Chief Investor Relations Officer | - |
| Mr. Jim Ellis | Chief Compliance Officer | - |
| Ms. Yvonne-Katrin Pucknat | Chief Marketing Officer | 49 |
監査リスク
1
取締役会リスク
7
報酬リスク
4
株主権利リスク
3
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for RMD, sourced from Markets Gazette.
- 3/10/2026POSITIVE3 Reasons Not to Sleep on ResMed Stock
ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.
- 3/4/2026POSITIVEHere's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.
via Markets Gazette